Enriching Medication Review with a Pharmacogenetic Profile – A Case of Tamoxifen Adverse Drug Reactions
Autor: | Henriette E. Meyer zu Schwabedissen, Chiara Jeiziner, Markus L. Lampert, Céline K Stäuble, Kurt E. Hersberger |
---|---|
Rok vydání: | 2021 |
Předmět: |
CYP2C9
0301 basic medicine Oncology medicine.medical_specialty CYP2D6 Pharmacist Case Report CYP2C19 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine medicine medication review PGx skin and connective tissue diseases pharmacogenetics Pharmacology Medication review tamoxifen business.industry medicine.disease 030104 developmental biology 030220 oncology & carcinogenesis Molecular Medicine business Tamoxifen Pharmacogenetics medicine.drug |
Zdroj: | Pharmacogenomics and Personalized Medicine |
ISSN: | 1178-7066 |
Popis: | Pharmacogenotyping is applied to determine the hereditable component of a patient's susceptibility to experience therapy failure and/or adverse drug reactions (ADRs). We present the case of a female patient diagnosed with breast cancer and treated with tamoxifen as recurrence therapy who experienced various ADRs. Pharmacogenotyping revealed variants in the cytochrome P450 (CYP) enzymes CYP2D6, CYP2C9, and CYP2C19. The observed genotype was associated with a risk for lower tamoxifen efficacy. Aside from the tamoxifen therapy, the comedication was reviewed for the influence of the patient’s pharmacogenetic profile. As a result of this pharmacist-led medication review with pharmacogenetic analyses, concrete genotype-driven recommendations for the treating gynecologist were compiled. This case revealed the added value of a large pharmacogenetic panel and the complexity of integrating a pharmacogenetic profile into a recommendation. |
Databáze: | OpenAIRE |
Externí odkaz: |